Comparison Between Coolprep and Picolyte for Bowel Cleansing
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators will compare with PEG+ascorbic acid and picosulfate+magnesium citrate about bowel preparation, patient's satisfaction, side effects to identify effectiveness of new bowel preparation drug.
| Condition |
|---|
|
Stasis; Colon |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | A Randomised Controlled Trial of a 2 Litre Polyethylene Glycol Solution + Ascorbic Acid Versus Sodium Picosulphate + Magnesium Citrate Solution for Bowel Cleansing Prior to Colonoscopy |
- Ottawa scale [ Time Frame: Ottawa scale will be checked at the end of the colonoscopy. Participants won't be followed up because of this study. ] [ Designated as safety issue: No ]
* Ottawa scale
Individual evaluation of right, mid, and left colon:
No liquid - 0 Minimal liquid, no suctioning required - 1 Suction required to see mucosa - 2 Wash and suction - 3 Solid stool,not washable - 4
Evaluation of the entire colon:
Overall quantity of fluid 0-2 minimal -0 moderate - 1 Large - 2
* Aronchick score scale Minimal liquid, visible more than 95% of colon mucosa - excellent Clear liquid covered 5~25% of mucosa, visible more than 90% of colon mucosa - good Solid stool, washable, visible more than 90% of colon mucosa - Fair Solid stool, not washable, visible less than 90% of colon mucosa not washable - Poor Bowel preparation is needed - Inadequate
- Patient satisfaction [ Time Frame: Questionnaires related with satisfaction and side effects will be written just befor colonoscopy. Participants won't be followed up because of this study. ] [ Designated as safety issue: No ]Taste, Comfort
- Symptoms related with bowel preparation [ Time Frame: Questionnaires related with side effects will be written just befor colonoscopy. Participants won't be followed up because of this study. ] [ Designated as safety issue: No ]Nausea, Vomiting, Abdominal discomfort, Abdominal distension, Headache, Dizziness, Numbness
| Estimated Enrollment: | 250 |
| Study Start Date: | January 2013 |
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Coolprep
A total of 2L A : NaCl 5.382g KCl 2.03g Sodium sulfate 15g Polyethylene glycol 3350 200.0g B : Ascorbic acid 9.4g Sodium ascorbate 11.8g
|
|
Picolyte
Sodium picosulfate 30.0mg Magnesium citrate 10.5g + 36.0g
|
Detailed Description:
The investigators can find easily colon cancer and poly by colonoscopy, but bowel preparation is very important to find the lesion. Desirable bowel preparation drug must be clearly removed stool, effective on colonoscopic finding and pathologic finding, quickly administrated agent and eliminated stool, comfort for patient, and less side effects.
PEG is very safe osmotic laxative. New agent(coolprep) which add ascorbic acid is less salty and less volume. Picosulfate+magnesium citrate(picolyte) taste orange, can be easily prepared bowel for colonoscopy by good taste and small volume. Magnesium with citrate acts like osmotic agent, picosulfate acts irritant agent.
The investigators will compare with PEG+ascorbic acid and picosulfate+magnesium citrate about bowel preparation, patient's satisfaction, side effects to identify effectiveness of new bowel preparation drug.
Eligibility| Ages Eligible for Study: | 19 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
This study will include a total of 250 patients. All patient randomized PEG+ascorbica acid(coolprep) and picosulfate magnesium citrate(picolyte), each group will include 125 patients.
The investigators decided sample size to 200 patients after comparing Ottawa scale. The investigators assumed there would be defference about 20 percent of bowel preparation between them. Recently, Ottawa scale of bowel preparation reported about 5 points. The investigators assumed that there could be differences between them about 1 point. The investigators decided each groups per 100 patients, if significance level was 0.05 and test power is 80 percent. The investigators start this study with a total of 220 patients because 10 percent of 200 patients could be drop out. The investigators readjust about 30 patients after interim analysis.
Inclusion Criteria:
- Age : over 19 years
- Who will be done colonoscopy
- Who accepted informed consent
Exclusion Criteria:
- Age : over 80 years
- Electrolyte imbalance
- Liver function test abnormality, ascites(over 2 times, >Child class B)
- ARF or CRF(GFS<30)
- Recent MI(< 6months) or Unstable angina pectoris
- Congestive heart failure(NYHA > 2)
- Inflammatory bowel disease
- Abdominal minor surgery
Contacts and Locations More Information
No publications provided
| Responsible Party: | Chung Jun Won, Professor, Gachon University Gil Medical Center |
| ClinicalTrials.gov Identifier: | NCT01774175 History of Changes |
| Other Study ID Numbers: | COOLPREPICOLYTE |
| Study First Received: | January 17, 2013 |
| Last Updated: | January 23, 2013 |
| Health Authority: | Korea: Food and Drug Administration |
Keywords provided by Gachon University Gil Medical Center:
|
Bowel preparation PEG with ascorbic acid Picosulfate |
Additional relevant MeSH terms:
|
Ascorbic Acid Picosulfate sodium Magnesium citrate Antioxidants Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protective Agents |
Physiological Effects of Drugs Vitamins Micronutrients Growth Substances Cathartics Gastrointestinal Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 17, 2013